GLP1R and Wolfram syndrome: In conclusion, we provide evidence for the beneficial impact of both short- and long-acting GLP-1R agonists in human pancreatic beta cells and neurons and humanised mice, thereby providing a strong preclinical basis to clinically test these drugs in people with Wolfram syndrome.